Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents.

Cancers (Basel) · 2022 · PMC9454536 · PMID 36077601

Europe PMC DOI

hedged sentences

0.2240

closest p · 4.5× alpha

0.2240

boldest claim

The sentences

did not reach statistical significancep = 0.224not close (p > 0.1)

While the addition of durvalumab numerically increased pCR rates in all patients, this increase did not reach statistical significance (53.4% vs. 44.2%; OR 1.45, 95% CI 0.80–2.63; p = 0.224).

also in 111,027 other papers

a favorable trendno p-value reported

Regarding survival, a favorable trend was found for the experimental arm; however, with a median follow-up of 20.6 months, the EFS outcomes were still immature (HR 0.76; 95% CI, 0.40 to 1.44) [ 63 ]. 3.3.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.